The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study.
Stefan Kubicka
Consultant or Advisory Role - Amgen; Roche
Honoraria - Amgen; Roche; Sanofi
Richard Greil
No relevant relationships to disclose
Thierry André
Consultant or Advisory Role - Amgen; Roche
Honoraria - Baxter ; Merck; Sanofi
Jaafar Bennouna
Consultant or Advisory Role - Amgen; Boehringer Ingelheim; Roche
Honoraria - Roche
Javier Sastre
Honoraria - Roche
Research Funding - Roche
Eric Van Cutsem
Research Funding - Roche
Roger Von Moos
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Novartis; Pfizer; Roche
Honoraria - Amgen; Roche
Research Funding - Roche
Expert Testimony - Amgen
Pia J. Osterlund
Consultant or Advisory Role - Roche
Honoraria - Roche
Priti Hegde
Employment or Leadership Position - Genentech
Stock Ownership - Genentech; Roche
Martina A. Sersch
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Stuart Osborne
Employment or Leadership Position - Roche
Frank Hermann
Employment or Leadership Position - Roche
Dirk Arnold
Consultant or Advisory Role - Amgen; Merck Serono; Roche
Honoraria - Amgen; Merck Serono; Roche
Research Funding - Roche